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We recently cloned the full-length cDNA of a tumour-associated protein. The recombinant protein expressed in bacteria and
referred to as angiocidin has potent antitumour activity in vivo and in vitro. Angiocidin inhibits tumour growth and angiogenesis by
inducing apoptosis in endothelial cells. Based on the sequence similarity of angiocidin to S5a, one of the major polyubiquitin
recognition proteins in eukaryotic cells, we postulated that the antiendothelial activity of angiocidin could be due in part to its
polyubiquitin binding activity. In support of this hypothesis, we show that angiocidin binds polyubiquitin in vivo with high affinity and
colocalises with ubiquitinated proteins on the surface of endothelial cells. Binding is blocked with an antiubiquitin antibody. Angiocidin
treatment of endothelial cells transfected with a proteasome fluorescent reporter protein showed a dose-dependent inhibition of
proteasome activity and accumulation of polyubiquitinated proteins. Full-length angiocidin bound polyubiquitin while three angiocidin
recombinant proteins whose putative polyubiquitin binding sites were mutated either failed to bind polyubiquitin or had significantly
diminished binding activity. The in vitro apoptotic activity of these mutants correlated with their polyubiquitin binding activity. These
data strongly argue that the apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity.
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Ubiquitin is a 76 amino-acid polypeptide that is one of the most
highly conserved proteins in nature (Hershko and Ciechanover,
1998). In 1978, ubiquitin was first characterised by Ciehanover
and Hershko as a heat stable polypeptide required for the
ATP-dependent proteolysis of proteins in rabbit reticulocytes
(Ciehanover et al, 1978). In the 1980s, the enzyme machinery of
this ATP-dependent protein degradation pathway was elucidated
by Driscoll and Goldberg (1990) and Rechsteiner et al (1993).
Today, it is recognised that ubiquitin/proteasome-dependent
proteolysis is critically involved in the regulation of many cellular
processes such as the cell cycle, differentiation, transcription,
antigen presentation and the selective degradation of misfolded
and damaged proteins (Jesenberger and Jentsch, 2002). Aberra-
tions of the ubiquitin/proteasome pathway have been thought to
play an important role in the pathogenesis of a number of diseases
such as Alzheimer’s disease, AIDS, autoimmune disease and
cancer. In cancer, proteasome inhibitors have shown antitumour
activity in animal models (Adams, 2001) and human cancer trials
(Chauhan et al, 2005).
We recently cloned the full-length cDNA for this protein and
expressed the protein in bacteria. The recombinant protein, referred
to as angiocidin, had potent antiangiogenic and antitumour activity
(Zhou et al, 2004). The recombinant protein induced endothelial
apoptosis when added to growth cultures of endothelial cells in full
media or when cells were plated on as little as 2mg of angiocidin
adsorbed on wells of a 96-well tissue culture plate.
A blast search of the full-length cDNA of angiocidin revealed
that the protein sequence had a high degree of homology with
two proteins, S5a (Young et al, 1998) and antisecretory factor
(Nilsson et al, 1992), both of which have identical sequences.
However, angiocidin differed from these proteins by three
additional amino acids in its carboxyl terminus (G255ER257).
Interestingly, although S5a and antisecretory factor have identical
protein sequences, they are reported to have different functions.
S5a is an internal polyubiquitin recognition subunit of the 26S
proteasome enzyme complex that binds polyubiquitin, the signal
that targets proteins for destruction. Antisecretory factor is a
secreted protein that inhibits water transport in the bowel induced
by cholera toxin. Therefore, S5a/antisecretory factor/angiocidin
represent a group of proteins with similar sequence but with
diverse functions. Moreover, the difference in structure between
S5a/antisecretory factor and angiocidin may additionally cause
these proteins to have significantly different conformations.
However, as described below both angiocidin, S5a, and antisecre-
tory factor share the same polypeptide sequences that have been
shown to mediate binding of polyubiquitinated proteins to S5a
(Young et al, 1998) and may therefore share common binding
interactions despite differences in cellular localization and function.
Based on the identity of the polyubiquitin-binding sequences
of angiocidin with S5a, a polyubiquitin recognition protein of the
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seukaryotic proteasome, we postulated that the antiangiogenic
activity of angiocidin could be mediated in part by its
polyubiquitin binding activity. In this report, we show that full-
length recombinant angiocidin inhibits endothelial proteasome
activity, while mutated angiocidin recombinant proteins whose
putative polyubiquitin binding sites at positions 216–220 and
290–294 have been replaced with alanines either partially or
completely lost their in vitro apoptotic activity. These mutant
proteins were either unable to bind polyubiquitin or displayed
greatly diminished binding activity while angiocidin bound with
high affinity. In addition, we show that angiocidin binds to
ubiquitinated proteins on the endothelial cell surface and that
this binding is blocked with antiubiquitin antibody. These data
strongly argue that the apoptotic in vitro antiendothelial activity of
angiocidin is dependent on its polyubiquitin binding activity.
Since many cellular processes such as growth control and cell
survival signals depend on a functional proteasome, our data
also suggest a novel strategy for the development of anticancer
drugs. This strategy proposes to develop polyubiquitin binding
peptides and proteins as anticancer therapeutics targeting cells
that overexpress ubiquitinated proteins and with a highly active
proteasome activity, which include tumour cells and endothelial
cells undergoing angiogenesis. These agents would represent a new
class of proteasome inhibitors that antagonise the signalling and
degradative functions of polyubiquitinated proteins leading to the
induction of cellular apoptosis.
MATERIALS AND METHODS
Antibodies and reagents
All chemicals were reagent grade unless specified otherwise. Mouse
monoclonal anti-his tag antibody was purchased from Qiagen,
Valencia, CA, USA. Polyubiquitin was purchased from BioMol,
Plymouth Meeting, PA, USA. Rabbit anti-human ubiquitin anti-
body was purchased from EMD Biosciences, Inc., San Diego, CA,
USA. Goat anti-rabbit IgG-Texas red conjugated antibody and
Alamar blue were purchased from Biosource, Camarillo, CA, USA.
Tissue culture media and serum were purchased from Fisher
Scientific, Pittsburgh, PA, USA. Monoclonal and polyclonal
antibodies against angiocidin were prepared from purified
recombinant protein (Covance, Denver, PA, USA). Fluorescein
isothiocyanate was purchased from Pierce Chemical Co., Rockford,
IL, USA. PD-10 desalting columns were purchased from Amersham
Pharmacia Biotech, Piscataway, NJ, USA. The ImmunoCruz
Staining System was purchased from Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA.
Angiocidin affinity chromatography
Human umbilical vein endothelial (HUVE) cell lysate was prepared
from a phosphate-buffered saline (PBS) washed monolayer of
2 10
7 HUVE cells. Monolayers were lysed with 1ml of 1  lysis
buffer (Cell Signaling, Beverly, MA, USA) containing 1 
concentration of Haltt protease inhibitor cocktail (Pierce
Chemical Co., Rockford, IL, USA) and 1mM 4-(2-aminoethyl)-
benzenesulphonyl fluoride (AEBSF). A 1ml angiocidin-Sepharose
column was prepared by coupling 1mg of angiocidin per ml of
CN-bromide activated Sepharose as described in the instructions
provided by Amersham Pharmacia, Piscataway, NJ, USA. The
column was washed with three column volumes of 10mM Tris
buffer, pH 7.6, containing 10mM 3-[(3-cholamidopropyl)-dimethyl-
ammonio]-1-propanesulphonate (Chaps) detergent, 1mM CaCl2,
and 1mM MgCl2 (wash buffer). Half the lysate was passed over the
column and the column was then washed with wash buffer. The
column was eluted in 10 1-ml fractions with elution buffer (0.1 M
Tris buffer, pH 10, containing 10mM Chaps, 1mM CaCl2, and 1mM
MgCl2). Protein peaks were pooled and dialysed against PBS
overnight at 41C. Aliquots of 40ml were evaluated for ubiquitin by
Western blot analysis. As a control, a bovine serum albumin
(BSA)-Sepharose column was prepared and HUVE extract applied
as described above for angiocidin-Sepharose. No protein peaks
were recovered from the BSA-Sepharose column.
Angiocidin conjugation with fluorescein isothiocyanate
(FITC)
An aliquot of 0.250ml of a 4mgml
 1 solution of angiocidin in PBS
was mixed with 0.10ml of 5% (Na2CO3), 1mg of fluorescein
isothiocyanate and the volume brought up to 1ml with distilled
water. The reaction was allowed to proceed for 1h and unreacted
fluorescein isothiocyanate was removed by chromatography of the
reaction mixture on a PD-10 desalting column equilibrated in PBS.
Peak fractions were collected, pooled and the protein concentra-
tion determined using the bicinchoninic acid (BCA) protein assay
obtained from Pierce.
Binding assays
The binding of angiocidin and its mutants to polyubiquitin was
measured using an enzyme-linked immunosorbent binding assay.
Briefly, 0.50mg of polyubiquitin in 50mlo f2 0 m M HEPES buffer,
pH 7.4 was dried overnight per well of a 96-well microtiter plate
(Nunc MaxiSorpt, Fisher Scientific, Pittsburg, PA, USA). Each well
was blocked for 30min with 200ml of 1% BSA in PBS, aspirated
and washed with 200ml of PBS. Each well was then incubated for
1.5h with 100ml of various concentrations of angiocidin or its
mutants in TBST (Tris-buffered saline, pH 7.4, containing 0.05%
Tween-20) at room temperature with shaking. Wells were
aspirated and washed three times with 250ml of TBST. Each well
was then incubated for 1h with 100ml of a 0.70mgml
 1 solution in
PBS of biotinylated rabbit antiangiocidin IgG prepared according
to the instructions provided with the EZ Link Sulpho-NHS
Biotinylation kit obtained from Pierce Chemical Co., Rockford,
IL, USA. Wells were then washed as above followed by a 30-min
incubation of 100ml of a 0.05mgml
 1 solution in PBS of
streptavidin coupled horseradish peroxidase (Pierce Chemical
Co., Rockford, IL, USA). Wells were aspirated, washed three times
and developed for 3–15min with 100ml of 1-step Ultra TMB
(3,30,5,50-tetramethylbenzidine) obtained from Pierce Chemical
Co., Rockford, IL, USA. Colour development was stopped by the
addition of 50ml of 0.50 M sulphuric acid. The plate was read in an
ELISA reader at 450nm.
Cell culture
HUVE cells were grown in EBM-2 medium (Cambrex Corporation,
East Rutherford, NJ, USA) supplemented with the EBM-2 bullet kit,
which contains 2% foetal bovine serum (FBS), and kept in 5% CO2
at 371C.
Binding of FITC angiocidin and staining of cell surface
ubiquitin on HUVE cells
HUVE cells, growing in two well chamber slides, were fixed with
4% paraformaldehyde for 30min at room temperature. Cells were
washed three times with PBS and the endogenous peroxidase
activity was blocked for 5min with Peroxidase Block from the
ImmunoCruz Staining System. After three washes with PBS, slides
were blocked with 5% horse serum in 0.1% BSA/PBS. For the direct
binding studies, cells were then treated in the dark with 2mgml
 1
FITC-angiocidin solution in PBS for 1h in the presence or absence
of 15mgml
 1 antiangiocidin monoclonal antibody, washed three
times and the slides coverslipped and viewed by fluorescence
microscopy at  400 magnification. In some experiments, cells
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 1 of mouse IgG or antiubiquitin
antiserum diluted 1–100 for 1h, washed and then treated with
FITC-labelled angiocidin as described above. For the colocalization
studies, slides were washed three times after treatment with
FITC-labelled angiocidin and then treated with a 1–500 dilution
of rabbit antiubiquitin serum for 1h. After three PBS washes, cells
were incubated with a 1–500 dilution of Texas red labelled goat
anti-rabbit IgG for 60min. After washing, slides were mounted and
viewed by fluorescence microscopy at  400 magnification.
Controls in which primary antibody was omitted were negative
(data not shown).
Cell transfection
To assess whether proteasome activity is inhibited by treatment
with angiocidin, HUVE cells transiently transfected with a
fluorescent reporter protein, which is engineered specifically to
be degraded by the proteasome, were evaluated in the presence or
absence of angiocidin. To measure proteasome activity in HUVE
cells, we used the Proteasome Sensor Vector, a reporter vector
designed to express the proteasome-sensitive fluorescent protein,
ZsProSensor-1 (Clontech, Palo Alto, CA, USA). ZsGreen is a
naturally occurring green fluorescent reef coral protein from
Zoanthus sp. having an excitation maximum of 496nm and an
emission maximum of 506nm. One day before the transfection,
HUVE cells were plated at a density of 1–3 10
5 cells in 2ml in a
35-mm culture dish (or six-well plate). After overnight incubation
when the cells were 50–80% confluent, serum containing EBM-2
medium was replaced with a sterile, serum-free EBM-2 medium.
Cell transfection was performed with FuGene6 (Roche Molecular
Biochemicals, Basel, Switzerland). FuGene6 reagent was used at a
concentration of 3ml/1mgD N Ap e rw e l lf o rt h et r a n s f e c t i o n .A t6–8h
after the transfection reaction, the transfection efficiency was
evaluated by measuring the fluorescence of the transfected green
fluorescent protein (GFP). In these experiments, transfection
efficiency exceeded 30% as assessed with cotransfection experiments
using a GFP (pGFP-C1 vector, Clontech, data not shown). Transfected
cells were monitored visually using fluorescence microscopy and
fluorescence changes were quantitated with a microplate fluorescence
reader (Bio-Tek Flx 800, Winooski, VT, USA).
Construction, expression and purification of his-tagged
recombinant angiocidin and its polyubiquitin defective
binding mutants
Angiocidin was cloned and expressed as previously described
(Zhou et al, 2004). Briefly, the full-length cDNA of angiocidin and
its mutants were ligated into pTricHis A vector so that the open
reading frame was in frame with the 6-histidine tag as previously
described (Zhou et al, 2004). The constructs were transformed
into Escherichia coli, and expression of the fusion protein was
induced with 1mM isopropyl-b-D thiogalactopyranoside (IPTG).
The purified proteins were recovered from Ni-NTA resin and the
total protein from bacterial extracts was subjected to SDS–PAGE
and Western blotting. The fusion proteins were finally eluted by
elution buffer containing a high concentration of imidazole.
Endotoxin was completely removed from recombinant proteins
by Triton X-114 phase separation as previously described (Aida
and Pabst, 1990).
Site-directed mutagenesis was performed to generate the three
polyubiquitin defective binding mutants M-1, M-2, M-1-2 using the
Quickchange site-mutagenesis kit (Stratagene, LaJolla, CA, USA).
Briefly, four primers were designed and used in this experiment.
These primers, oriented from the 50 to 30 end are as follows:
Primer 1: GTGCTGATCCTGAGGCTGCCGCAGCCGCTCGTG
TATCTATGGAAG
Primer 2: CTTCCATAGATACACGAGCGGCTGCGGCAGCCTC
AGGATCAGCAC
Primer 3: CTGAGGAAGAGCAGGCTGCTGCTGCCGCACAGAT
GTCCCTGCAG
Primer 4: CTGCAGGGACATCTGTGCGGCAGCAGCCTGCTCTT
CCTCAG.
Primers 1 and 2 were used to generate mutant M-1. Primers 3
and 4 were used to generate mutant M-2. The double-mutant
M-1-2 was generated using primer 1 and 2 on the template cDNA
obtained from mutant M-1 and primers 3 and 4 were used on the
template cDNA obtained from mutant M-2.
Viability assay
We evaluated the effect of angiocidin on cell viability using the
Alamar blue assay. In this assay, 10ml Alamar blue, a metabolizable
dye, was added to a 100ml of media in a 96-well plate containing
15000 cells per well. After 2–3h, the number of viable cells in the
plate was proportional to the difference in absorbance at 562 and
595nm as read in a microtitre plate reader.
Western blots
Proteins were analysed under reducing conditions by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE),
and the gel electroblotted onto a polyvinylidene fluoride (PVDF)
membrane. Gels (12% polyacrylamide) were used in the study and
were purchased from GeneMate ISC BioExpress, Kaysville, UT,
USA. The membrane was developed using the chemiluminescence
(ECL) system (Amersham, Arlington Heights, IL, USA).
RESULTS
Polyubiquitin binding activity of angiocidin
Based on the fact that angiocidin contains peptide domains
homologous to the polyubiquitin binding domain of S5a, one of
the major polyubiquitin recognition subunits of the proteasome,
we speculated that the antitumour activity and apoptotic activity
of angiocidin may in part be mediated by peptide regions of
angiocidin that bind polyubiquitin. Thus far we have shown
that the thrombospondin-1 binding domain of angiocidin partially
regulates its apoptotic activity in vitro while abolishing its in vivo
antitumour activity (Zhou et al, 2004). However, we could not
render the molecule completely inactive in vitro by mutating the
TSP-1 binding site alone. Therefore, we sought to find other
domains of the molecule that mediate its apoptotic activity. We
reasoned that the polyubiquitin binding domains of angiocidin
could render it a competitive inhibitor of the cellular proteasome
by complexing with polyubiquitinated proteins both on the cell
surface as well as in the cytoplasm. These proteins complexed
with angiocidin might then be prevented from degradation by the
endogenous cellular proteasome. Since many cellular proteins that
regulate apoptosis are degraded by the proteasome, inhibition of
the proteasome would be expected to result in the induction of
apoptosis (Jesenberger and Jentsch, 2002). We expressed three
his-tagged recombinant angiocidin molecules that had their
putative polyubiquitin binding domains substituted for alanines
as was performed for S5a (Young et al, 1998). For S5a at least two
polyubiquitin binding sites have been reported to reside in an
alpha helical region of the protein near the carboxyl terminus of
the molecule (Young et al, 1998). These sites have been reported
to differ in affinity for polyubiquitin. Therefore, we created the
following mutants of angiocidin based on the polyubiquitin
binding structure of S5a: M-1 has I290AYAM294, a low-affinity
polyubiquitin-binding site substituted with alanines. M-2 has
L216ALAL220, a high-affinity polyubiquitin-binding site substituted
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swith alanines. M-1-2 has both sites substituted with alanines
(Figure 1). The purified recombinant angiocidin and its alanine
substitution mutants contained a 55kDa polypeptide that cross-
reacted with an antiangiocidin monoclonal antibody, as revealed
by Western blot analysis (Figure 1B).
To confirm that mutants M-1-2, M-1, and M-2 lost their
polyubiquitin binding activity, we tested their binding activity in
an ELISA binding assay in which polyubiquitin was adsorbed on
a microtitre plate. Bound angiocidin or its mutants was detected
with a biotinylated-labelled rabbit antiangiocidin antibody raised
against recombinant angiocidin (Figure 2). Polyubiquitin was
purchased commercially and contains a range of ubiquitin
polymers from 1 to 50kDa. The data in Figure 2 show that mutant
M-1, and M-1-2 completely lost their polyubiquitin binding
activity while angiocidin and M-2 bound saturably with a Kd of
0.041 and 15nM, respectively. Although M-2 bound saturably,
its Kd was over 300 fold higher than that of angiocidin and the
maximal bound protein was four-fold lower than that for
angiocidin (compare Figure 2A with Figure 2B).
In vitro apoptotic activity of angiocidin is dependent on its
polyubiquitin binding activity
Angiocidin and its polyubiquitin-binding mutants were compared
for their endothelial cell apoptotic activity using the Alamar blue
viability assay. We found that mutants M-1, containing residues
I290 AYAM294 substituted by alanines, and M-1-2, containing
residues I290 AYAM294 and L216ALAL220 substituted by alanines,
lost their apoptotic inducing activity as well as their polyubiquitin
binding activity. However, M-2, containing L216ALAL220 substi-
tuted with alanines, still bound polyubiquitin with a favourable Kd
of 1.52nM, while displaying four-fold lower maximal binding than
angiocidin. In contrast to the other mutants that completely lost
their polyubiquitin binding activity and their apoptotic activity,
M-2 had a two-fold diminished apoptotic activity as compared to
angiocidin (Figure 3B). Many more cells although rounded were
still viable in the M-2 treatment group (Figure 3A). Cells were
treated overnight with angiocidin and its mutants. These results
indicate that the extent to which angiocidin binds polyubiquitin
correlates with its in vitro apoptotic activity.
Antibody to ubiquitin mimics the apoptotic activity of
angiocidin
To provide additional evidence that angiocidin partially exerts its
apoptotic activity on HUVE cells by binding ubiquitinated
proteins, we compared the activity of angiocidin with that of an
antibody against ubiquitin (Figure 3C). Cells were treated
overnight. Both angiocidin and the antiubiquitin antibody induced
cell death approximately to the same extent (as approximated by
trypan blue dye exclusion), suggesting that both proteins interact
with ubiquitinated proteins either on the cell surface or internally
to induce cell death.
Angiocidin binds ubiquitinated proteins in vivo and
in vitro
To evaluate the interaction of angiocidin with ubiquitinated
proteins in vivo, we investigated the cell surface interaction of
HUVE cells with angiocidin and ubiquitin. Angiocidin was
derivatised with the fluorescent marker FITC. Derivatised angio-
cidin did not lose any of its endothelial apoptotic activity as
compared to uncoupled angiocidin (data not shown). We found
that HUVE cells fixed with paraformaldehyde bound FITC-labelled
angiocidin (Figure 4A, E and H). In general, FITC-labelled
angiocidin appeared to localise to filopodia, the periphery of the
cell, and in punctate spots showing a nonuniform distribution.
In the presence of a monoclonal antibody to angiocidin and a
polyclonal antibody to ubiquitin, the binding was significantly
inhibited (compare A with C and D of Figure 4). In contrast,
control IgG did not significantly inhibit binding of FITC-
angiocidin (compare A with B of Figure 4). Angiocidin and
ubiquitin both localised to filopodia and to punctate patches
distributed near the periphery of the cells (Figure 4 E–J).
M-1   (I290AYAM294)( A 290AAAA294)
M-2   (L216ALAL220)( A 216AAAA220)
M-1-2         (L216ALAL220---I290AYAM294)
(A216AAAA220---A290AAAA294)
55 kDa
Angio M-1-2 M-2 M-1
A
B
Figure 1 Polyubiquitin deficient binding mutants. (A) Description of
altered sequences in the mutated angiocidin recombinant proteins. (B)
Western blot of recombinant angiocidin. Proteins were probed with a
1mgml
 1 polyclonal antiangiocidin IgG as previously described (Zhou et al,
2004).
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Figure 2 Binding of angiocidin and its polyubiquitin deficient mutants to
polyubiquitin. Wells of a 96-well plate were coated with 0.5mgo f
polyubiquitin and binding was performed as described in the Materials and
Methods section. Lines were fitted to a rectangular hyperbola and Kd and
maximal bound angiocidin were calculated using GraphPad Prizm software
(San Diego, CA, USA). (A) Binding at a high protein concentration range.
(B) Angiocidin titrated down to a lower range allowing for the
determination of a Kd value. Error bars represent the standard deviation.
The experiments shown are representative of at least two separate
experiments.
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sColocalization was most apparent in the areas showing strong
binding such as in punctate patches, cell periphery and filopodia
(Figure 4G and J).
To identify ubiquitinated proteins recognised by angiocidin,
HUVE cell detergent extracts were chromatographed on an
angiocidin affinity column and the column eluates were Western
blotted with antiubiquitin antibody. We found three major
ubiquitinated proteins from HUVE cells that bound to the column.
These proteins ranged in molecular weight from 40 to 200kDa
(Figure 5A). We have tentatively identified one of the bands
isolated by angiocidin affinity chromatography using MALDI-TOF
peptide fingerprinting. The 150kDa band gave rise to peptide
fragments matching those of tissue transglutaminase 2. We are
currently investigating the significance of this finding in relation-
ship to mechanisms of angiogenesis. Tissue transglutaminase is
thought to mediate angiogenesis by crosslinking the extracellular
matrix (Haroon et al, 1999).
Angiocidin induces HUVE cells to accumulate
polyubiquitinated proteins and inhibits their
proteasome activity
To further provide evidence that angiocidin exerts its apoptotic
activity by interfering with endogenous ubiquitin binding proteins,
we evaluated the level of protein ubiquination in HUVE cells
treated with angiocidin. We found that cells treated with
angiocidin or plated on angiocidin-coated tissue culture plates
contained significantly higher levels of ubiquitinated proteins than
cells plated on plastic or treated with buffer as revealed by Western
blot analysis (Figure 5B). Three ubiquitinated proteins having
molecular weights of approximately 200000, 61000, and 43000Da
increased in angiocidin-treated cells as compared to controls
(Figure 5B). Similar proteins were found to bind to an angiocidin
affinity column (Figure 5A).
To provide additional data that components of the cellular
ubiquitin recognition system are inhibited by angiocidin, we
assayed proteasome activity of cells treated with angiocidin. HUVE
cells were transiently transfected with a fluorescent reporter
protein that is specifically degraded by the proteasome and the
activity of the reporter was measured in the presence or absence
of angiocidin. To measure proteasome activity in HUVE cells, we
used the Proteasome Sensor Vector, a reporter vector designed to
express the proteasome-sensitive fluorescent protein, ZsPro-
Sensor-1 (Clontech, Palo Alto, CA, USA). This protein is a C-
terminal fusion of ZsGreen with the mouse ornithine decarbox-
ylase degradation domain (amino acids 410–461). ZsGreen is a
naturally occurring green fluorescent coral reef protein from
Zoanthus sp. with an excitation maximum of 496nm and an
emission maximum of 506nm. The addition of the mouse
ornithine decarboxylase degradation domain targets the protein
for rapid degradation by the proteasome. In this assay, transfected
cells internally accumulate the fluorescent undegraded protein and
fluoresce green when the proteasome is inhibited. As a positive
control, cells were treated for 3–5h with 10mM of a known
proteasome inhibitor ALLN (N-acetyl-Leu-Leu-Norleucinal). This
peptide–aldehyde adduct is freely cell permeable and inhibits the
neutral cysteine protease activity of the proteasome. In these
experiments, transfection efficiency exceeded 30% as assessed with
cotransfection experiments using a GFP (pGFP-C1 vector,
Clontech, data not shown). Transfected cells were monitored
visually using fluorescence microscopy and fluorescence changes
were quantitated with a microplate fluorescence reader. We
observed a dose-dependent increase in fluorescence when HUVE
cells growing in serum-containing media were treated with
increasing concentrations of angiocidin as quantitated with a
fluorescent ELISA reader (Figure 6B) and visualised by fluores-
cence microscopy (Figure 6A). These results provide strong
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Figure 3 Effect of angiocidin, its mutants and antiubiquitin antibody on
the viability of HUVE cells. Cells were plated on 96-well microtitre plates
coated with either 1mg of angiocidin or its mutants. Cells were cultured
overnight and viability measured using the Alamar blue assay as previously
described (Zhou et al, 2004). (A) Cells photographed using Hoffman
interference microscopy at a magnification of  100. (B) Viability
measurements using the Alamar blue assay. The experiment is representa-
tive and shows the mean of three replicates and error bars represent the
standard error of the mean. (C) Effect of antiubiquitin antibody on the
viability of HUVE cells. HUVE cells were grown for 24h on 96-well plates
coated with 1mg of angiocidin or M-1-2 or treated with 10ml of control
serum or rabbit antiubiquitin antibody. Cells were photographed using
Hoffman interference microscopy at a magnification of  200.
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sevidence in support of the hypothesis that angiocidin inhibits
cellular proteasome activity.
DISCUSSION
We previously isolated a protein from lung tumour extracts by
peptide affinity chromatography using the type 1 TSP-1 repeat
peptide CSVTCG (Tuszynski et al, 1993). The protein was cloned
from a prostate cell cDNA library and the full-length cDNA was
nearly identical to that reported for S5a, a ubiquitin recognition
subunit of the 19S proteasome subunit and antisecretory factor,
a secreted protein that regulates water secretion by the large bowel
(Johansson et al, 1997). We have named our cloned protein
angiocidin due to its in vitro antiangiogenic activity (1). Like S5a,
angiocidin contains a polyubiquitin binding sequence and like
antisecretory factor angiocidin is secreted into the circulation. We
have also previously shown that recombinant angiocidin has
potent antitumour as well as endothelial cell apoptotic activities,
and that the antitumour and endothelial apoptotic activities of
angiocidin depend partially on its TSP-1 binding activity (Zhou
et al, 2004). Furthermore, in these studies, we also found that
recombinant angiocidin injected into tumour-bearing mice bound
to the tumour stroma and induced massive tumour cell death.
It is well recognised that protein degradation mediated by
cellular proteasome activity contributes to the malignant pheno-
type. Recognition of these polyubiquitinated proteins both on the
cell surface and internally contributes to cellular proteasome
activity. Therefore, we postulated that putative polyubiquitin
binding domains of angiocidin may contribute to its ability to
induce endothelial cell apoptosis. Two sequences present in
angiocidin are identical to the sequences in S5a that have been
shown to bind polyubiquitin (Young et al, 1998). These two
sequences were mutated by substituting alanines for amino acids
present in residues 216–220 and 290–294. Three mutant
angiocidin recombinant proteins were expressed (Figure 1). Since
residues I290–M294 of S5a have been reported to contain a low-
affinity polyubiquitin-binding site (Young et al, 1998), mutant M-1
angiocidin containing I290–M294 substituted with A290 AAAA294
was expressed and purified. Additionally, since residues L216–l220
of S5a have also been reported to contain a high-affinity
polyubiquitin-binding site (Young et al, 1998), we also elected to
express mutant M-2 containing L216–L220 substituted with
A216AAAA220. Finally, mutant M-1-2 having both polyubiquitin
binding sites substituted with alanines was also expressed. We
found that all the polyubiquitin binding mutants displayed either
no or diminished binding to polyubiquitin immobilised on
microtitre dishes. Angiocidin bound with a Kd of 0.041nM, while
M-2 bound with a Kd of 15nM and M-1 and M-1-2 showed no
detectable binding (Figure 2).
The functional consequence of mutating the polyubiquitin
binding site of angiocidin was investigated using the Alamar blue
viability assay. In our previous study (Zhou et al, 2004), we used
this assay to show that angiocidin induces endothelial cell
Figure 4 Angiocidin colocalises with ubiquitinated proteins in HUVE cells. HUVE cells, growing in glass chamber slides, were fixed with 4%
paraformaldehyde and treated with 2mgml
 1 FITC-angiocidin and costained with antiubiquitin antibody, as described in Material and Methods. After
washing, slides were mounted and viewed by fluorescence microscopy at  400 magnification. In panels A–D, cells were only treated with 2mgml
 1 FITC-
angiocidin or 2mgml
 1 FITC-angiocidin in the presence of 15mgml
 1 of control mouse IgG, or antiangiocidin mouse monoclonal IgG, or a 1–100 dilution of
antiubiquitin antiserum. In panels E–J, slides were treated with 2mgml
 1 FITC-angiocidin and costained with antiubiquitin antibody. Panels E and H show
FITC-angiocidin staining, panels F and I show antiubiquitin staining, and panels G and J are composites of FITC-angiocidin and antiubiquitin staining showing
yellow areas of colocalization of angiocidin and antiubiquitin stained areas. Controls in which primary antibody was omitted were negative (data not shown).
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of a 96-well-microtitre dish caused cells to round and undergo
apoptosis in as short a time as 5h. When we tested our
polyubiquitin binding-deficient mutants, we found that mutants
M-1 and M-1-2 completely lost their apoptotic activity, while M-2
although still active displayed at least 50% less activity than
angiocidin (Figure 3). The in vitro apoptotic activity of angiocidin
appeared to directly correlate with its capacity to bind poly-
ubiquitin. Mutants M-1 and M-1-2 that bound no polyubiquitin
displayed no in vitro HUVE cell apoptotic activity, while mutant
M-2 that still bound polyubiquitin had a two-fold lower apoptotic
activity as compared to angiocidin. Furthermore, in the absence
of a consideration of possible protein conformational changes
induced by substituting alanines in the active polyubiquitin
binding sites of angiocidin, these results also suggest that residues
I290–M294 play a more important role than residues L216–L220 in
the binding of polyubiquitin and the induction of endothelial cell
apoptosis.
Our data regarding the polyubiquitin deficient binding mutants
suggest that angiocidin induces cell apoptosis in HUVE cells by
inhibiting cellular proteasome activity by interaction with the
cellular polyubiquitin recognition system. In support of this
hypothesis, we show that angiocidin-treated HUVE cells accumu-
late ubiquitinated proteins as seen by Western blot analysis of total
cell lysates prepared from cells treated with angiocidin for
increasing lengths of time (Figure 5B). The functional consequence
of this increase in ubiquitin protein accumulation was evaluated
using a proteasome reporter assay. We found that both angiocidin
and a known proteasome inhibitor, N-acetyl-leucinyl-leucinyl-
norleucinal (ALLN), caused a time-dependent increase in the
fluorescence of HUVE cells transfected with the proteasome
reporter protein (Figure 6A and B). These results strongly suggest
that angiocidin inhibits cellular proteasome activity.
To further provide evidence that angiocidin induces apoptosis
in HUVE cells by antagonizing the cellular ubiquitin recognition
system of the proteasome, we performed experiments designed to
show that angiocidin binds to ubiquitinated proteins in HUVE
cells. In the first experiment, HUVE cell lysates were fractionated
by angiocidin affinity chromatography (Figure 5A). We detected at
least three ubiquitinated protein bands ranging in molecular
weight from 150 to 43kDa. These proteins are currently being
characterised by mass spectral analysis. Preliminary mass spectral
analysis of one of these protein bands indicates homology with
tissue transglutaminase. The significance of this observation is
currently under investigation. Consistent with these results we also
found that angiocidin bound unpermeabilised HUVE cells and
colocalised with surface-expressed ubiquitin in a peripheral as well
as a punctuate pattern of colocalization (Figure 4). Colocalization
was also observed on filopodia. We were able to block FITC-
angiocidin binding with an antibody to angiocidin and ubiquitin,
indicating that the angiocidin binding was specific and that it
occurred through cell surface ubiquitin. These results strongly
suggest that angiocidin binds to cell surface ubiquitinated HUVE
cell proteins. Consistent with these results is our observation that
an antibody to ubiquitin was found to mimic the apoptotic activity
of angiocidin (Figure 3). Like angiocidin, we postulate that
antiubiquitin antibody must bind to HUVE cell surface proteins
and induce cell death. Taken together these results are consistent
with the concept that cell-surface ubiquitinated proteins mediate
HUVE cell apoptosis.
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Figure 5 Angiocidin binds HUVE polyubiquitinated proteins as well as
inducing HUVE cells to accumulate polyubiquitinated proteins. In panel A,
HUVE cell eluates obtained from an angiocidin- or BSA-Sepharose column
were analysed on SDS–PAGE under reducing conditions and Western
blotted for polyubiquitinated proteins using purified rabbit antipolyubiquitin
antiserum at a dilution of 1–500. The blot was developed by enhanced
chemiluminescence. Approximately 5mg of column eluate and 1mgo f
purified ubiquitin were analysed. Lane 1, purified ubiquitin; Lane 2,
angiocidin affinity column eluate; Lane 3, BSA column eluate. In panel B,
HUVE cells grown in 24-well plates were treated with either buffer or with
100mgml
 1 angiocidin for 5 or 24h, harvested and Western blotted for
polyubiquitin as described in panel A. Lane 1, purified ubiquitin; Lane 2,
buffer treated cells; Lane 3, cells treated with angiocidin for 6h; Lane 4, cells
treated with angiocidin for 24h.
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Figure 6 Angiocidin inhibits proteasome activity of HUVE cells. HUVE
cells were transiently transfected with a proteasome reporter plasmid
encoding ZsGreen, a fluorescent protein degraded by the proteasome, and
plated in 96-well culture plates in serum-containing media for quantitative
fluorescence measurements or in six-well plates for photography. After
cells attached, they were either treated with buffer (control), angiocidin
(100–200mgml
 1), or ALLN (10mgml
 1), a known proteasome inhibitor.
At various times, fluorescence intensity was measured (B) and the cells
were photographed after 3h as viewed by fluorescence and phase
microscopy at  200 magnification (A).
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protein degradation associated with cellular house-keeping func-
tions such as the elimination of damaged proteins. However, it has
become clear in recent years that post-translational modification
of proteins with ubiquitin is a major cellular regulatory mecha-
nism. Both the turnover and activity of many cell surface receptors
are regulated by ubiquitination. A notable example is epidermal
growth factor receptor (EGFR). This receptor or its splice variants
are upregulated in many malignant tumours such as human
glioma and center carcinoma. Upon ligand activation, EGFR is
rapidly polyubiquitinated by specific adaptor proteins (Schmidt
et al, 2003). Our results confirm the presence of numerous
ubiquitinated proteins on the surface of endothelial cells as
revealed by immunostaining of paraformaldehyde-fixed cells. In
this report we show that fluorescence-conjugated angiocidin binds
to the surface of endothelial cells and colocalises with ubiquiti-
nated proteins. We speculate that angiocidin binds to critical
receptors important in cell adhesion and growth perhaps through
regions of these proteins derivatised with ubiquitin. It is
conceivable that these proteins could be adhesion receptors that
mediate critical cellular adhesive events important in angiogenesis
and survival. Angiocidin could bind these proteins either through
domains that become polyubiquitinated during ligand binding
such has been observed for EGFR or through other domains that
interact with angiocidin. Angiocidin-ligated receptors may be
inhibited from turnover and subsequently lose their ligand binding
activity. These possibilities are currently being investigated.
Our results do not exclude the importance of matrix binding
domains of angiocidin in promoting its antitumour activity such
as the TSP-1 domain identified in our previous study (Zhou et al,
2004). We postulate that these matrix binding domains of
angiocidin help localise angiocidin to the tumour environment
that is rich in matrix proteins such as TSP-1 and collagen.
Angiocidin is then able to interact with cell surface ubiquitinated
proteins and exert its inhibitory effect on angiogenesis.
The implications of these studies regarding angiocidin as a
potential anticancer therapeutic are considerable. Angiocidin
could be used to target tumour cells and tumour vasculature by
binding to specific polyubiquitinated proteins expressed on
tumour and tumour vasculature. In fact, our preliminary studies
have shown that angiocidin accumulates on the tumour vascu-
lature and tumour stroma of mice bearing Lewis Lung carcinoma
(Zhou et al, 2004). Angiocidin would then exert its antiangiogen-
esis activity.
Finally, in a much broader context, our results suggest that
targeting ubiquitinated proteins may represent a new paradigm for
the development of novel antiangiogenic cancer therapeutics.
Ubiquitin protein antagonists may not only inhibit cellular
proteasome activity but may also target surface proteins important
for cell growth and angiogenesis. Therefore, the identification of
small molecule ubiquitin binding compounds may represent an
attractive strategy for anticancer drug discovery.
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